Shoulder Injections for Shoulder Osteoarthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial compares two types of injections for shoulder osteoarthritis. It targets patients with moderate to severe pain and limited mobility. One injection combines a lubricating substance with an anti-inflammatory drug, while the other uses only an anti-inflammatory drug. The goal is to see which injection provides better pain relief and improves joint function. Diclofenac etalhyaluronate (DF-HA) has been studied for its effectiveness and safety in treating osteoarthritis in various joints, showing significant pain relief particularly in the hip joint.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you have had a cortisone injection in the last 6 months or a platelet-rich plasma or hyaluronic acid injection in the last 12 months, you cannot participate.
Is the treatment of shoulder osteoarthritis with triamcinolone injections safe?
How does the drug Triamcinolone Hexacetonide combined with hyaluronic acid differ from other treatments for shoulder osteoarthritis?
This drug combination is unique because it combines Triamcinolone Hexacetonide, a steroid that reduces inflammation, with hyaluronic acid, which acts as a lubricant in the joint, potentially offering both pain relief and improved joint function. This dual approach may provide benefits over treatments that use only one of these components.16789
What data supports the effectiveness of the drug for shoulder osteoarthritis?
Who Is on the Research Team?
Patrice Tétreault, MD FRCSC
Principal Investigator
CHUM
Are You a Good Fit for This Trial?
This trial is for adults aged 20-90 with moderate to severe primary shoulder osteoarthritis, who can read and understand French or English. They must have pain of at least 4/10 on the visual scale and be able to fill out questionnaires. Exclusions include those with certain shoulder injuries, recent related treatments, pregnancy, joint diseases like avascular necrosis or infections, cognitive impairments that prevent questionnaire comprehension.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-infiltration Evaluation
Standard x-ray and MRI examination, demographic data collection, medical history review, and completion of 2 questionnaires
Treatment
Participants receive a single intra-articular infiltration of either Cingal or cortisone under fluoroscopy
Follow-up
Participants complete electronic questionnaires and maintain a medication diary at 1, 3, and 6 months post-infiltration
What Are the Treatments Tested in This Trial?
Interventions
- Triamcinolone Hexacetonide
- Triamcinolone Hexacetonide and hyaluronic acid
Triamcinolone Hexacetonide is already approved in United States, Canada, European Union for the following indications:
- Osteoarthritis
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Bursitis
- Tendinitis
- Gouty arthritis
- Osteoarthritis
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Bursitis
- Tendinitis
- Gouty arthritis
- Osteoarthritis
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Bursitis
- Tendinitis
- Gouty arthritis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Centre hospitalier de l'Université de Montréal (CHUM)
Lead Sponsor